Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance.

Safi H, Gopal P, Lingaraju S, Ma S, Levine C, Dartois V, Yee M, Li L, Blanc L, Ho Liang HP, Husain S, Hoque M, Soteropoulos P, Rustad T, Sherman DR, Dick T, Alland D.

Proc Natl Acad Sci U S A. 2019 Sep 5. pii: 201907631. doi: 10.1073/pnas.1907631116. [Epub ahead of print]

PMID:
31488707
2.

Lack of association of novel mutation Asp397Gly in aftB gene with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis.

Giri A, Safi H, Cabibbe AM, Gupta S, Narang A, Tyagi G, Shrivastava K, Kumar C, Kumar Sharma N, Lingaraju S, Trovato A, Battaglia S, Cirillo DM, Bose M, Alland D, Varma-Basil M.

Tuberculosis (Edinb). 2019 Mar;115:49-55. doi: 10.1016/j.tube.2019.01.004. Epub 2019 Jan 25.

PMID:
30948176
3.

Multiplex Detection of Three Select Agents Directly from Blood by Use of the GeneXpert System.

Banada PP, Deshpande S, Banik S, Shah D, Koshy R, Patel B, Kwiatkowski R, Persing D, Alland D.

J Clin Microbiol. 2019 Apr 26;57(5). pii: e00036-19. doi: 10.1128/JCM.00036-19. Print 2019 May.

PMID:
30842226
4.

Transmission phenotype of Mycobacterium tuberculosis strains is mechanistically linked to induction of distinct pulmonary pathology.

Verma S, Bhatt K, Lovey A, Ribeiro-Rodrigues R, Durbin J, Jones-López EC, Palaci M, Vinhas SA, Alland D, Dietze R, Ellner JJ, Salgame P.

PLoS Pathog. 2019 Mar 6;15(3):e1007613. doi: 10.1371/journal.ppat.1007613. eCollection 2019 Mar.

5.

Bacterial Factors and Relapse after Tuberculosis Therapy.

Colangeli R, Kim S, Alland D.

N Engl J Med. 2019 Jan 10;380(2):197-198. doi: 10.1056/NEJMc1813645. No abstract available.

PMID:
30625067
6.

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.

Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R, Singleton E, Zimmerman MD, Ho HP, Dartois V, Connell N, Alland D, Freundlich JS.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):601-606. doi: 10.1016/j.bmcl.2018.12.053. Epub 2018 Dec 24.

PMID:
30600207
7.

Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.

Kumar P, Capodagli GC, Awasthi D, Shrestha R, Maharaja K, Sukheja P, Li SG, Inoyama D, Zimmerman M, Ho Liang HP, Sarathy J, Mina M, Rasic G, Russo R, Perryman AL, Richmann T, Gupta A, Singleton E, Verma S, Husain S, Soteropoulos P, Wang Z, Morris R, Porter G, Agnihotri G, Salgame P, Ekins S, Rhee KY, Connell N, Dartois V, Neiditch MB, Freundlich JS, Alland D.

MBio. 2018 Dec 18;9(6). pii: e02101-17. doi: 10.1128/mBio.02101-17.

8.

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J.

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

9.

Bacterial Factors That Predict Relapse after Tuberculosis Therapy.

Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams.

N Engl J Med. 2018 Aug 30;379(9):823-833. doi: 10.1056/NEJMoa1715849.

10.

Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method.

Walters E, Scott L, Nabeta P, Demers AM, Reubenson G, Bosch C, David A, van der Zalm M, Havumaki J, Palmer M, Hesseling AC, Ncayiyana J, Stevens W, Alland D, Denkinger C, Banada P.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00781-18. doi: 10.1128/JCM.00781-18. Print 2018 Sep.

11.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

12.

Polymorphisms in Rv3806c (ubiA) and the upstream region of embA in relation to ethambutol resistance in clinical isolates of Mycobacterium tuberculosis from North India.

Giri A, Gupta S, Safi H, Narang A, Shrivastava K, Kumar Sharma N, Lingaraju S, Hanif M, Bhatnagar A, Menon B, Alland D, Varma-Basil M.

Tuberculosis (Edinb). 2018 Jan;108:41-46. doi: 10.1016/j.tube.2017.10.003. Epub 2017 Oct 12.

PMID:
29523326
13.

Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.

Acuña-Villaorduña C, Jones-López EC, Fregona G, Marques-Rodrigues P, Gaeddert M, Geadas C, Hadad DJ, White LF, Pereira Dutra Molina L, Vinhas S, Ribeiro-Rodrigues R, Salgame P, Palaci M, Alland D, Ellner JJ, Dietze R.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701578. doi: 10.1183/13993003.01578-2017. Print 2018 Jan.

14.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

15.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Dec 7;23(12):1499. doi: 10.1038/nm1217-1499a.

16.

Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.

Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM; study team.

Lancet Infect Dis. 2018 Jan;18(1):76-84. doi: 10.1016/S1473-3099(17)30691-6. Epub 2017 Nov 30. Erratum in: Lancet Infect Dis. 2018 Feb 21;:.

17.

Host blood RNA signatures predict the outcome of tuberculosis treatment.

Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE; Catalysis TB–Biomarker Consortium.

Tuberculosis (Edinb). 2017 Dec;107:48-58. doi: 10.1016/j.tube.2017.08.004. Epub 2017 Aug 12.

18.

Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner JJ, Dorman SE, Alland D.

N Engl J Med. 2017 Sep 14;377(11):1043-1054. doi: 10.1056/NEJMoa1614915.

19.

Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.

Kidwai S, Park CY, Mawatwal S, Tiwari P, Jung MG, Gosain TP, Kumar P, Alland D, Kumar S, Bajaj A, Hwang YK, Song CS, Dhiman R, Lee IY, Singh R.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00969-17. doi: 10.1128/AAC.00969-17. Print 2017 Nov.

20.

The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing.

Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D.

MBio. 2017 Aug 29;8(4). pii: e00812-17. doi: 10.1128/mBio.00812-17.

21.

Incident Mycobacterium tuberculosis infection in household contacts of infectious tuberculosis patients in Brazil.

Jones-López EC, Acuña-Villaorduña C, Fregona G, Marques-Rodrigues P, White LF, Hadad DJ, Dutra-Molina LP, Vinhas S, McIntosh AI, Gaeddert M, Ribeiro-Rodrigues R, Salgame P, Palaci M, Alland D, Ellner JJ, Dietze R.

BMC Infect Dis. 2017 Aug 18;17(1):576. doi: 10.1186/s12879-017-2675-3.

22.

Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.

Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF; AIDS Clinical Trials Group A5295; Tuberculosis Trials Consortium Study 34 Teams.

J Clin Med. 2017 Aug 7;6(8). pii: E78. doi: 10.3390/jcm6080078.

23.

Rapid Detection of Bacillus anthracis Bloodstream Infections by Use of a Novel Assay in the GeneXpert System.

Banada PP, Deshpande S, Russo R, Singleton E, Shah D, Patel B, Burday M, Koshy R, Wang Q, Jones M, Gall A, Lokhov S, Kwiatkowski R, Persing D, Connell N, Alland D.

J Clin Microbiol. 2017 Oct;55(10):2964-2971. doi: 10.1128/JCM.00466-17. Epub 2017 Jul 26.

24.

Serologic Responses in Childhood Pulmonary Tuberculosis.

Nonyane BAS, Nicol MP, Andreas NJ, Rimmele S, Schneiderhan-Marra N, Workman LJ, Perkins MD, Joos T, Broger T, Ellner JJ, Alland D, Kampmann B, Dorman SE, Zar HJ.

Pediatr Infect Dis J. 2018 Jan;37(1):1-9. doi: 10.1097/INF.0000000000001683.

25.

Strains of Mycobacterium tuberculosis transmitting infection in Brazilian households and those associated with community transmission of tuberculosis.

Vinhas SA, Jones-López EC, Ribeiro Rodrigues R, Gaeddert M, Peres RL, Marques-Rodrigues P, de Aguiar PPL, White LF, Alland D, Salgame P, Hom D, Ellner JJ, Dietze R, Collins LF, Shashkina E, Kreiswirth B, Palaci M.

Tuberculosis (Edinb). 2017 May;104:79-86. doi: 10.1016/j.tube.2017.03.003. Epub 2017 Mar 16.

26.

Diagnostic accuracy of the Xpert® MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis.

Lange B, Khan P, Kalmambetova G, Al-Darraji HA, Alland D, Antonenka U, Brown T, Balcells ME, Blakemore R, Denkinger CM, Dheda K, Hoffmann H, Kadyrov A, Lemaitre N, Miller MB, Nikolayevskyy V, Ntinginya EN, Ozkutuk N, Palacios JJ, Popowitch EB, Porcel JM, Teo J, Theron G, Kranzer K.

Int J Tuberc Lung Dis. 2017 May 1;21(5):493-502. doi: 10.5588/ijtld.16.0702. Review.

PMID:
28399963
27.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526a. No abstract available.

PMID:
28388609
28.

A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells.

Sukheja P, Kumar P, Mittal N, Li SG, Singleton E, Russo R, Perryman AL, Shrestha R, Awasthi D, Husain S, Soteropoulos P, Brukh R, Connell N, Freundlich JS, Alland D.

MBio. 2017 Feb 14;8(1). pii: e02022-16. doi: 10.1128/mBio.02022-16.

29.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

30.

Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings.

Dharan NJ, Blakemore R, Sloutsky A, Kaur D, Alexander RC, Ghajar M, Musser KA, Escuyer VE, Rowlinson MC, Crowe S, Laniado-Laborin R, Valli E, Nabeta P, Johnson P, Alland D.

BMC Infect Dis. 2016 Dec 20;16(1):764.

31.

Sensitive Detection of Francisella tularensis Directly from Whole Blood by Use of the GeneXpert System.

Banada PP, Deshpande S, Chakravorty S, Russo R, Occi J, Meister G, Jones KJ, Gelhaus CH, Valderas MW, Jones M, Connell N, Alland D.

J Clin Microbiol. 2016 Dec 28;55(1):291-301. doi: 10.1128/JCM.01126-16. Print 2017 Jan.

32.

Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.

Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, Lokhov S, Liu X, Xu P, Zhang G, Via LE, Shen Q, Ruan X, Yuan X, Zhu HZ, Viazovkina E, Shenai S, Rowneki M, Lee JS, Barry CE 3rd, Gao Q, Persing D, Kwiatkawoski R, Jones M, Gall A, Alland D.

J Clin Microbiol. 2016 Dec 28;55(1):183-198. doi: 10.1128/JCM.01771-16. Print 2017 Jan.

33.

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P.

J Clin Microbiol. 2016 Dec;54(12):3028-3033. Epub 2016 Oct 12.

34.

Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S.

Nat Med. 2016 Oct;22(10):1094-1100. doi: 10.1038/nm.4177. Epub 2016 Sep 5. Erratum in: Nat Med. 2017 Apr 7;23 (4):526. Nat Med. 2017 Dec 7;23 (12 ):1499.

35.

A snapshot of the predominant single nucleotide polymorphism cluster groups of Mycobacterium tuberculosis clinical isolates in Delhi, India.

Varma-Basil M, Narang A, Chakravorty S, Garima K, Gupta S, Kumar Sharma N, Giri A, Zozio T, Couvin D, Hanif M, Bhatnagar A, Menon B, Niemann S, Rastogi N, Alland D, Bose M.

Tuberculosis (Edinb). 2016 Sep;100:72-81. doi: 10.1016/j.tube.2016.07.007. Epub 2016 Jul 25.

PMID:
27553413
36.

Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.

Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, Dodd LE, Via LE, Barry CE 3rd, Walzl G, Alland D.

PLoS One. 2016 Aug 10;11(8):e0160062. doi: 10.1371/journal.pone.0160062. eCollection 2016.

37.

Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study.

Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, Narang R, Paramasivan CN, Hillemann D, Nabeta P, Amisano D, Alland D, Cobelens F, Boehme CC.

J Clin Microbiol. 2016 Aug;54(8):1984-91. doi: 10.1128/JCM.03036-15. Epub 2016 May 18.

38.

Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis.

Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL, German S, Cho E, Lee JI, Cho SN, Kim CT, Alland D, Safi H.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4101-5. doi: 10.1128/AAC.03002-15. Print 2016 Jul.

39.

High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Lanoix JP, Tasneen R, O'Brien P, Sarathy J, Safi H, Pinn M, Alland D, Dartois V, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul.

40.

A Novel Sample Processing Method for Rapid Detection of Tuberculosis in the Stool of Pediatric Patients Using the Xpert MTB/RIF Assay.

Banada PP, Naidoo U, Deshpande S, Karim F, Flynn JL, O'Malley M, Jones M, Nanassy O, Jeena P, Alland D.

PLoS One. 2016 Mar 23;11(3):e0151980. doi: 10.1371/journal.pone.0151980. eCollection 2016.

41.

Analytical and Clinical Evaluation of the Epistem Genedrive Assay for Detection of Mycobacterium tuberculosis.

Shenai S, Armstrong DT, Valli E, Dolinger DL, Nakiyingi L, Dietze R, Dalcolmo MP, Nicol MP, Zemanay W, Manabe Y, Hadad DJ, Marques-Rodrigues P, Palaci M, Peres RL, Gaeddert M, Armakovitch S, Nonyane BA, Denkinger CM, Banada P, Joloba ML, Ellner J, Boehme C, Alland D, Dorman SE.

J Clin Microbiol. 2016 Apr;54(4):1051-7. doi: 10.1128/JCM.02847-15. Epub 2016 Feb 10.

42.

Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D; AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams.

Clin Infect Dis. 2016 May 1;62(9):1081-8. doi: 10.1093/cid/ciw035. Epub 2016 Feb 2.

43.

Improved diagnostic sensitivity for tuberculous meningitis with Xpert(®) MTB/RIF of centrifuged CSF.

Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, Alland D, Meya DB, Rhein J, Boulware DR.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1209-15. doi: 10.5588/ijtld.15.0253.

44.

Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance.

Roh SS, Smith LE, Lee JS, Via LE, Barry CE 3rd, Alland D, Chakravorty S.

PLoS One. 2015 May 4;10(5):e0126257. doi: 10.1371/journal.pone.0126257. eCollection 2015.

45.

Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis.

Salamon H, Yamaguchi KD, Cirillo DM, Miotto P, Schito M, Posey J, Starks AM, Niemann S, Alland D, Hanna D, Aviles E, Perkins MD, Dolinger DL.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S50-7. doi: 10.1093/infdis/jiu816. Review.

46.

Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S39-49. doi: 10.1093/infdis/jiu682. Review.

47.

Improving the sensitivity of the Xpert MTB/RIF assay on sputum pellets by decreasing the amount of added sample reagent: a laboratory and clinical evaluation.

Dharan NJ, Amisano D, Mboowa G, Ssengooba W, Blakemore R, Kubiak RW, Armstrong DT, Jones M, Manabe YC, Joloba ML, Ellner JJ, Dorman SE, Alland D.

J Clin Microbiol. 2015 Apr;53(4):1258-63. doi: 10.1128/JCM.03619-14. Epub 2015 Feb 4.

48.

Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing.

Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE 3rd, Alland D.

J Clin Microbiol. 2015 Jan;53(1):43-51. doi: 10.1128/JCM.02059-14. Epub 2014 Oct 22.

49.

Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in Uganda.

Ssengooba W, Nakiyingi L, Armstrong DT, Cobelens FG, Alland D, Manabe YC, Dorman SE, Ellner JJ, Joloba ML.

PLoS One. 2014 Sep 15;9(9):e107595. doi: 10.1371/journal.pone.0107595. eCollection 2014.

50.

Molecular diagnosis of rifampin-monoresistant tuberculosis in Indian patients: problems with a discordance analysis.

Alland D, Michael JS, Denkinger CM, Cirillo DM.

J Clin Microbiol. 2014 Sep;52(9):3503. doi: 10.1128/JCM.01607-14. No abstract available.

Supplemental Content

Loading ...
Support Center